{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:12:28Z","timestamp":1775560348979,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>Since the outbreak of SARS\u2010CoV\u20102, also known as COVID\u201019, conflicting theories have circulated on the influence of angiotensin\u2010converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on incidence and clinical course of COVID\u201019, but data are scarce. The COvid MEdicaTion (COMET) study is an observational, multinational study that focused on the clinical course of COVID\u201019 (i.e. hospital mortality and intensive care unit [ICU] admission), and included COVID\u201019 patients who were registered at the emergency department or admitted to clinical wards of 63 participating hospitals. Pharmacists, clinical pharmacologists or treating physicians collected data on medication prescribed prior to admission. The association between the medication and composite clinical endpoint, including mortality and ICU admission, was analysed by multivariable logistic regression models to adjust for potential confounders. A total of 4870 patients were enrolled. ACEi were used by 847 (17.4%) patients and ARB by 761 (15.6%) patients. No significant association was seen with ACEi and the composite endpoint (adjusted odds ratio [OR] 0.94; 95% confidence interval [CI] 0.79 to 1.12), mortality (OR 1.03; 95%CI 0.84 to 1.27) or ICU admission (OR 0.96; 95%CI 0.78 to 1.19) after adjustment for covariates. Similarly, no association was observed between ARB and the composite endpoint (OR 1.09; 95%CI 0.90 to 1.30), mortality (OR 1.12; OR 0.90 to 1.39) or ICU admission (OR 1.21; 95%CI 0.98 to 1.49). In conclusion, we found no evidence of a harmful or beneficial effect of ACEi or ARB use prior to hospital admission on ICU admission or hospital mortality.<\/jats:p>","DOI":"10.1111\/bcp.14751","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T22:43:00Z","timestamp":1611873780000},"page":"3301-3309","source":"Crossref","is-referenced-by-count":7,"title":["No association between use of angiotensin\u2010converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID\u201019 in the COvid MEdicaTion (COMET) study"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6647-6584","authenticated-orcid":false,"given":"Roos S. G.","family":"Sablerolles","sequence":"first","affiliation":[{"name":"Departments of Internal Medicine Erasmus MC University Medical Centre  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-9471","authenticated-orcid":false,"given":"Freija E. F.","family":"Hogenhuis","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Erasmus MC University Medical Centre  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-6415","authenticated-orcid":false,"given":"Melvin","family":"Lafeber","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine Erasmus MC University Medical Centre  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-7898","authenticated-orcid":false,"given":"Bob P. A.","family":"van de Loo","sequence":"additional","affiliation":[{"name":"Digitalis Rx BV  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8425-6139","authenticated-orcid":false,"given":"Sander D.","family":"Borgsteede","sequence":"additional","affiliation":[{"name":"Department of Clinical Decision Support Health Base Foundation  Houten The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-7128","authenticated-orcid":false,"given":"Eric","family":"Boersma","sequence":"additional","affiliation":[{"name":"Cardiology Erasmus MC University Medical Centre  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-7765","authenticated-orcid":false,"given":"Jorie","family":"Versmissen","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine Erasmus MC University Medical Centre  Rotterdam The Netherlands"},{"name":"Hospital Pharmacy Erasmus MC University Medical Centre  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7128-8801","authenticated-orcid":false,"given":"Hugo","family":"van der Kuy","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Erasmus MC University Medical Centre  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"COMET Research Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2762"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03712"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","unstructured":"van deVeerdonkF NeteaMG Van DeurenM et al.Kinins and Cytokines in COVID\u201019: A Comprehensive Pathophysiological Approach. Preprints2020:1\u201329.","DOI":"10.20944\/preprints202004.0023.v1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2006.03.001"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa041"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0360-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21656"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000782"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002472"},{"key":"e_1_2_10_16_1","unstructured":"BauerA MassbergS.Stopping ACE\u2010inhibitors in COVID\u201019 (ACEI\u2010COVID). ClinicalTrialsgov identifier NCT04353596.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04353596. Accessed May 8 2020."},{"key":"e_1_2_10_17_1","unstructured":"CohenJ HanffT Corrales\u2010MedinaV ByrdJ Viau ColindresR.Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID). ClinicalTrialsgov identifier NCT04338009.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04338009Accessed May 8 2020."},{"key":"e_1_2_10_18_1","unstructured":"LazaroL BhattA.Ramipril for the Treatment of COVID\u201019 (RAMIC). ClinicalTrialsgov identifier NCT04366050.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04366050. Accessed May 8 2020."},{"key":"e_1_2_10_19_1","unstructured":"vanKimmenadeR GommansF deJagerP HassingR.Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS\u2010COV\u20102 (COVID\u201019) Infection Disease. ClinicalTrialsgov identifier NCT04335786.https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04335786. Accessed May 8 2020."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002329"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0141076814562718"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta7310"},{"key":"e_1_2_10_23_1","first-page":"2191\/94","article-title":"Declaration of Helsinki; ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2012.06.008"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008975"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317134"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1624"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15312"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31030-8"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2021225"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2020822"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2021225"},{"key":"e_1_2_10_35_1","unstructured":"ESC Guidance for the Diagnosis and Management of CV Disease during the COVID\u201019 Pandemic. European Society of Cardiology;2020."},{"key":"e_1_2_10_36_1","unstructured":"White SolaruK WrightJ.COVID\u201019 and Use of Drugs Targeting the Renin\u2010Angiotensin\u2010System. American College of Cardiology;2020."},{"key":"e_1_2_10_37_1","unstructured":"A statement from the International Society of Hypertension on COVID\u201019. International Society of Hypertension;2020."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14751","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:13:14Z","timestamp":1693354394000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/bcp.14751"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14751","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}